Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms
Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …
Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis
D Siskind, S Orr, S Sinha, O Yu, B Brijball… - The British Journal of …, 2022 - cambridge.org
BackgroundTreatment-resistant schizophrenia (TRS) is associated with high levels of
functional impairment, healthcare usage and societal costs. Cross-sectional studies may …
functional impairment, healthcare usage and societal costs. Cross-sectional studies may …
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
CU Correll, A Martin, C Patel, C Benson, R Goulding… - Schizophrenia, 2022 - nature.com
Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Objectives: This guideline provides recommendations for the clinical management of
schizophrenia and related disorders for health professionals working in Australia and New …
schizophrenia and related disorders for health professionals working in Australia and New …
[图书][B] The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia
American Psychiatric Association - 2020 - books.google.com
The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …
Schizophrenia seeks to reduce these substantial psychosocial and public health …
Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review
M Solmi, A Murru, I Pacchiarotti… - … and clinical risk …, 2017 - Taylor & Francis
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs)
have revolutionized psychiatric care in terms of facilitating discharge from hospital and …
have revolutionized psychiatric care in terms of facilitating discharge from hospital and …
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
CU Correll, J Detraux, J De Lepeleire… - World …, 2015 - Wiley Online Library
People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …
population. This excess mortality is mainly due to physical illness. Next to mental illness …
Psychosis
DB Arciniegas - CONTINUUM: lifelong learning in neurology, 2015 - journals.lww.com
Abstract Purpose of Review: Psychosis is a common and functionally disruptive symptom of
many psychiatric, neurodevelopmental, neurologic, and medical conditions and an …
many psychiatric, neurodevelopmental, neurologic, and medical conditions and an …
Increased mortality in schizophrenia due to cardiovascular disease–a non-systematic review of epidemiology, possible causes, and interventions
PA Ringen, JA Engh, AB Birkenaes, I Dieset… - Frontiers in …, 2014 - frontiersin.org
Background: Schizophrenia is among the major causes of disability worldwide and the
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing …
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing …
Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study
CU Correll, JW Newcomer… - American Journal of …, 2020 - Am Psychiatric Assoc
Objective: A combination of olanzapine and the opioid receptor antagonist samidorphan is
under development for the treatment of schizophrenia and bipolar I disorder. The single …
under development for the treatment of schizophrenia and bipolar I disorder. The single …